|
| Status |
Public on Oct 06, 2020 |
| Title |
ITC + LPV sample 1 |
| Sample type |
SRA |
| |
|
| Source name |
whole cell
|
| Organism |
Candidozyma auris |
| Characteristics |
drug treatment: lopinavir+itraconazole
|
| Treatment protocol |
Exponential-phase cultures of C. auris AR0390 were treated with either DMSO (1%), lopinavir (10 µg/ml), itraconazole (1 µg/ml), or a combination of both drugs.
|
| Growth protocol |
Candida aurus (AR0390) cells
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Ambion Ribopure yeast kit
Illumina TruSeq kit
2x150 on a NovaSeq 6000
|
| |
|
| Library strategy |
RNA-Seq |
| Library source |
transcriptomic |
| Library selection |
cDNA |
| Instrument model |
Illumina NovaSeq 6000 |
| |
|
| Data processing |
fastp was used to observe read quality
fastp was used to trim data
HISAT2 (v2.1) to align reads to the reference genome
FeatureCounts (v2.1) was used to count reads mapping to genes
edgeR Bioconductor package (v3.16.5) to identify differentially expressed genes
Genome_build: Candida auris NCBI reference genome version B11221
Supplementary_files_format_and_content: counts
|
| |
|
| Submission date |
Apr 08, 2020 |
| Last update date |
Oct 06, 2020 |
| Contact name |
Nadia Marie Atallah |
| Organization name |
Purdue University
|
| Department |
Center for Cancer Research
|
| Street address |
201 S. University St
|
| City |
West Lafayette |
| State/province |
IN |
| ZIP/Postal code |
47907 |
| Country |
USA |
| |
|
| Platform ID |
GPL28368 |
| Series (1) |
| GSE148341 |
Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant Candida auris |
|
| Relations |
| BioSample |
SAMN14560800 |
| SRA |
SRX8083234 |
